The safety of new oral anticoagulants for ischemic stroke and systemic embolism prevention in females with atrial fibrillation
The prevalence of atrial fibrillation is lower in females than in men, but the risk of stroke and systemic thromboembolism is comparable or even higher. Administration of anticoagulant therapy does not modify this difference. Two classes of non-vitamin K antagonist oral anticoagulants were studied i...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Amaltea Medical Publishing House
2021-03-01
|
| Series: | Romanian Journal of Neurology |
| Subjects: | |
| Online Access: | https://rjn.com.ro/articles/2021.1/RJN_2021_1_Art-01.pdf |
| _version_ | 1819139917285949440 |
|---|---|
| author | Despina-Manuela Toader Ileana Neaca Alina Paraschiv Rodica Musetescu |
| author_facet | Despina-Manuela Toader Ileana Neaca Alina Paraschiv Rodica Musetescu |
| author_sort | Despina-Manuela Toader |
| collection | DOAJ |
| description | The prevalence of atrial fibrillation is lower in females than in men, but the risk of stroke and systemic thromboembolism is comparable or even higher. Administration of anticoagulant therapy does not modify this difference. Two classes of non-vitamin K antagonist oral anticoagulants were studied in atrial fibrillation: direct thrombin inhibitors, like Dabigatran, and activated factor X inhibitors, like Rivaroxaban, Apixaban and Edoxaban. Response to oral anticoagulants could differ between the gender. This medication was evaluated in phase III randomized controlled trials. Non-vitamin K antagonist oral anticoagulants have been proved more efficacious than Warfarin for stroke and systemic embolism prevention in women, but conclusions regarding the safety and the bleeding are heterogeneous. As in men, before
prescribing a NOAC to a female with AF, the stroke and the bleeding risk have to be carefully estimated. It is important that future studies to be targeted on comparison between of non-vitamin K antagonist oral anticoagulants versus Warfarin in females with non-valvular atrial fibrillation. |
| first_indexed | 2024-12-22T11:30:17Z |
| format | Article |
| id | doaj.art-3d34f2f00c6f4a249a3c0251f07eab5c |
| institution | Directory Open Access Journal |
| issn | 1843-8148 2069-6094 |
| language | English |
| last_indexed | 2024-12-22T11:30:17Z |
| publishDate | 2021-03-01 |
| publisher | Amaltea Medical Publishing House |
| record_format | Article |
| series | Romanian Journal of Neurology |
| spelling | doaj.art-3d34f2f00c6f4a249a3c0251f07eab5c2022-12-21T18:27:38ZengAmaltea Medical Publishing HouseRomanian Journal of Neurology1843-81482069-60942021-03-0120151410.37897/RJN.2021.1.1The safety of new oral anticoagulants for ischemic stroke and systemic embolism prevention in females with atrial fibrillationDespina-Manuela Toader0Ileana Neaca1Alina Paraschiv2Rodica Musetescu3EuroEchoLab, Craiova, Romania; Cardiology Center, Emergency Hospital, Craiova, RomaniaSanocare Clinic, Craiova, Romania Cardiology Center, Emergency Hospital, Craiova, RomaniaFaculty of Medicine, University of Medicine and Pharmacy, Craiova, RomaniaThe prevalence of atrial fibrillation is lower in females than in men, but the risk of stroke and systemic thromboembolism is comparable or even higher. Administration of anticoagulant therapy does not modify this difference. Two classes of non-vitamin K antagonist oral anticoagulants were studied in atrial fibrillation: direct thrombin inhibitors, like Dabigatran, and activated factor X inhibitors, like Rivaroxaban, Apixaban and Edoxaban. Response to oral anticoagulants could differ between the gender. This medication was evaluated in phase III randomized controlled trials. Non-vitamin K antagonist oral anticoagulants have been proved more efficacious than Warfarin for stroke and systemic embolism prevention in women, but conclusions regarding the safety and the bleeding are heterogeneous. As in men, before prescribing a NOAC to a female with AF, the stroke and the bleeding risk have to be carefully estimated. It is important that future studies to be targeted on comparison between of non-vitamin K antagonist oral anticoagulants versus Warfarin in females with non-valvular atrial fibrillation.https://rjn.com.ro/articles/2021.1/RJN_2021_1_Art-01.pdfnon-vka oral anticoagulantsatrial fibrillationfemalessafety |
| spellingShingle | Despina-Manuela Toader Ileana Neaca Alina Paraschiv Rodica Musetescu The safety of new oral anticoagulants for ischemic stroke and systemic embolism prevention in females with atrial fibrillation Romanian Journal of Neurology non-vka oral anticoagulants atrial fibrillation females safety |
| title | The safety of new oral anticoagulants for ischemic stroke and systemic embolism prevention in females with atrial fibrillation |
| title_full | The safety of new oral anticoagulants for ischemic stroke and systemic embolism prevention in females with atrial fibrillation |
| title_fullStr | The safety of new oral anticoagulants for ischemic stroke and systemic embolism prevention in females with atrial fibrillation |
| title_full_unstemmed | The safety of new oral anticoagulants for ischemic stroke and systemic embolism prevention in females with atrial fibrillation |
| title_short | The safety of new oral anticoagulants for ischemic stroke and systemic embolism prevention in females with atrial fibrillation |
| title_sort | safety of new oral anticoagulants for ischemic stroke and systemic embolism prevention in females with atrial fibrillation |
| topic | non-vka oral anticoagulants atrial fibrillation females safety |
| url | https://rjn.com.ro/articles/2021.1/RJN_2021_1_Art-01.pdf |
| work_keys_str_mv | AT despinamanuelatoader thesafetyofneworalanticoagulantsforischemicstrokeandsystemicembolismpreventioninfemaleswithatrialfibrillation AT ileananeaca thesafetyofneworalanticoagulantsforischemicstrokeandsystemicembolismpreventioninfemaleswithatrialfibrillation AT alinaparaschiv thesafetyofneworalanticoagulantsforischemicstrokeandsystemicembolismpreventioninfemaleswithatrialfibrillation AT rodicamusetescu thesafetyofneworalanticoagulantsforischemicstrokeandsystemicembolismpreventioninfemaleswithatrialfibrillation AT despinamanuelatoader safetyofneworalanticoagulantsforischemicstrokeandsystemicembolismpreventioninfemaleswithatrialfibrillation AT ileananeaca safetyofneworalanticoagulantsforischemicstrokeandsystemicembolismpreventioninfemaleswithatrialfibrillation AT alinaparaschiv safetyofneworalanticoagulantsforischemicstrokeandsystemicembolismpreventioninfemaleswithatrialfibrillation AT rodicamusetescu safetyofneworalanticoagulantsforischemicstrokeandsystemicembolismpreventioninfemaleswithatrialfibrillation |